ASH 2023 | Venetoclax in combination with azacitidine for patients with treatment-naïve HR-MDS
Jacqueline Garcia, MD, Dana-Farber Cancer Institute, Boston, MA, shares the findings of a study evaluating the safety and efficacy of venetoclax in combination with azacitidine in patients with treatment-naïve higher-risk myelodysplastic syndromes (HR-MDS; NCT02942290). Dr Garcia summarizes the mutational profile of the patients enrolled in this study and then discusses the main results. The combination of venetoclax plus azacitidine resulted in deep responses, a median overall survival (OS) of 26 months, and 40% of patients were able to be bridged to stem cell transplantation (SCT). A Phase III study is ongoing, and Dr Garcia further emphasizes the need to improve therapeutic approaches for patients with HR-MDS. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
